Development of novel humanized CD19 / BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms
British Journal of Haematology · 2024-10 · 205 (4) · 1361-1373
DOI: 10.1111/bjh.19631 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 03.07.2024. Verfasst von Sungui Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Antigens, CD19, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, B-Cell Activation Factor Receptor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Key Research & Development Program of Jiangsu Province, Key Research Project of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
Chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable efficacy in treating advanced B‐cell malignancies by targeting CD19, but antigen‐negative relapses and immune responses triggered by murine‐derived antibodies remain significant challenges, necessitating the development of novel humanized multitarget CAR‐T therapies. Here, we engineered a second‐generation 4‐1BB‐CD3ζ‐based CAR construct incorporating humanized CD19 single‐chain variable fragments (scFvs) and BAFFR single‐variable domains on heavy chains (VHHs), also known as nanobodies. The resultant CAR‐T cells, with different constructs, were functionally compared both in vitro and in vivo. We found that the optimal tandem and bicistronic (BI) structures retained respective antigen‐binding abilities, and both demonstrated specific activation when stimulated with target cells. At the same time, BI CAR‐T cells (BI CARs) exhibited stronger tumour‐killing ability and better secretion of interleukin‐2 and tumour necrosis factor‐alpha than single‐target CAR‐T cells. Additionally, BI CARs showed less exhaustion phenotype upon repeated antigen stimulation and demonstrated more potent and persistent antitumor effects in mouse xenograft models. Overall, we developed a novel humanized CD19/BAFFR bicistronic CAR (BI CAR) based on a combination of scFv and VHH, which showed potent and sustained antitumor ability both in vitro and in vivo, including against tumours with CD19 or BAFFR deficiencies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Iaso Biotherapeutics Co. Ltd., Nanjing, Jiangsu, China.
- Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Sungui Wu, Taochao Tan, Xiaoqing Dong, Bing Chen
Förderung
- Key Research & Development Program of Jiangsu Province
- Key Research Project of Jiangsu Provincial Health Commission
Zitieren
APA
Wu, S., Luo, Q., Li, F., Zhang, S., Zhang, C., Liu, J., Shao, B., Hong, Y., Tan, T., Dong, X., & Chen, B. (2024). Development of novel humanized CD19 / BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms. British Journal of Haematology, 205(4), 1361-1373. https://doi.org/10.1111/bjh.19631
Vancouver
Wu S, Luo Q, Li F, Zhang S, Zhang C, Liu J, et al. Development of novel humanized CD19 / BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms. British Journal of Haematology. 2024;205(4):1361-1373. doi:10.1111/bjh.19631
BibTeX
@article{Wu2024,
author = {Wu, Sungui and Luo, Qian and Li, Feiyu and Zhang, Suwen and Zhang, Cuiling and Liu, Jianwei and Shao, Bang and Hong, Yang and Tan, Taochao and Dong, Xiaoqing and Chen, Bing},
title = {Development of novel humanized CD19 / BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms},
journal = {British Journal of Haematology},
year = {2024},
volume = {205},
number = {4},
pages = {1361--1373},
doi = {10.1111/bjh.19631}
}
EUVIMED